BEDFORD, Mass.--(BUSINESS WIRE)--Apr. 26, 2018--
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company
focused on the formulation, development, and commercialization of
innovative therapies for diseases and conditions of the eye, today
announced that it will report first quarter ended March 31, 2018
financial results on Tuesday, May 8, 2018. Following distribution of the
earnings release via wire services, the Ocular Therapeutix management
team will host a live conference call and webcast at 4:30 p.m. Eastern
Time to review the Company’s financial results and provide a general
business update.
The live webcast can be accessed by visiting the Investors section of
the Company’s website at investors.ocutx.com.
Please connect at least 15 minutes prior to the live webcast to ensure
adequate time for any software download that may be needed to access the
webcast. Alternatively, please call (844) 464-3934 (U.S.) or (765)
507-2620 (International) to listen to the live conference call. The
conference ID number for the live call will be 3148379. An archive of
the webcast will be available until August 8, 2018 on the Company’s
website.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
formulation, development, and commercialization of innovative therapies
for diseases and conditions of the eye using its proprietary
hydrogel-based formulation technology. Ocular Therapeutix’s lead product
candidate, DEXTENZA™ (dexamethasone insert) 0.4 mg for intracanalicular
use, has completed Phase 3 clinical development for the treatment of
ocular pain and inflammation following ophthalmic surgery. OTX-TP
(travoprost insert) is in Phase 3 clinical development for the reduction
of intraocular pressure in patients with glaucoma and ocular
hypertension. The Company’s earlier stage assets include OTX-TIC, a
sustained release travoprost intracameral implant for the reduction of
intraocular pressure in patients with glaucoma and ocular hypertension,
as well as sustained release intravitreal implants for the treatment of
retinal diseases. These implants include the development of OTX-TKI, a
tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron,
an extended release protein-based anti-vascular endothelial growth
factor (VEGF) trap. Ocular Therapeutix's first product, ReSure® Sealant,
is FDA-approved to seal corneal incisions following cataract surgery.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180426006660/en/
Source: Ocular Therapeutix, Inc.
Investors
Ocular Therapeutix
Donald Notman
Chief
Financial Officer
dnotman@ocutx.com
or
Westwicke
Partners
Chris Brinzey
Managing Director
chris.brinzey@westwicke.com
or
Media
Ocular
Therapeutix
Scott Corning
Senior Vice President, Commercial
scorning@ocutx.com